Last reviewed · How we verify
BBR 3464
BBR 3464 is a small molecule inhibitor of the PI3K delta subunit.
BBR 3464 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | BBR 3464 |
|---|---|
| Sponsor | Theradex |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
BBR 3464 works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in a decrease in inflammation and potentially reducing the severity of autoimmune diseases.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
Key clinical trials
- BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery (PHASE2)
- BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BBR 3464 CI brief — competitive landscape report
- BBR 3464 updates RSS · CI watch RSS
- Theradex portfolio CI